EU Publishes 2026 Implementing Regulation on Medical Device Conformity Assessment: Notified Bodies Must Standardize Quotations, Time Limits and Recertification

Commission Implementing Regulation (EU) 2026/977 Published in the Official Journal

On 5 May 2026, Commission Implementing Regulation (EU) 2026/977 was published in the Official Journal of the European Union. The Regulation governs the conformity assessment activities carried out by notified bodies under Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). The Commission summarizes the objective of the measure as improving consistency, predictability and efficiency.

What the Regulation Sets Out: Four Core Elements

The Regulation establishes uniform requirements for notified body conformity assessment activities, built around four main elements.

• Quotations: when a notified body issues a quotation to a manufacturer, it must provide a reliable estimate of the overall services required and the associated costs.
• Time limits and "stop-the-clock": maximum processing times are set for key stages, including application review and contract signing, quality management system audits, product verification, decision-making and certificate issuance, and assessment of changes. The clock may be paused where, for example, the manufacturer has not provided complete documentation.
• Monitoring and publication: notified bodies must establish a system to track the duration and cost of conformity assessment activities, and must publish this information annually.
• Recertification: the procedures and timetable for recertification are clarified, reducing uncertainty in the certificate renewal process.

When the Regulation Applies

The Regulation applies from 25 February 2027. The only exception is the annual reporting obligation on duration and costs, which applies from 1 January 2028. This means notified bodies and manufacturers have a preparatory period between now and February 2027.

Who Is Bound — and Who Is Not

These uniform requirements bind the notified bodies designated to carry out MDR and IVDR conformity assessments. They do not directly create new technical documentation or clinical requirements for manufacturers; what changes is the assessment process itself — how quotations are issued, how long each stage may take at most, how recertification is scheduled, and whether duration and costs are made public. Device classification, clinical evaluation and post-market obligations remain governed by the MDR, the IVDR and their associated documents.

Why the EU Took This Step

Notified bodies carry out pre-market assessment of device safety and performance and provide ongoing post-market oversight. In the Commission's view, making the operation of notified bodies more predictable and more transparent is a necessary condition for the proper functioning of the regulatory system, and also helps support the supply of devices on the EU market. The Regulation sits within the EU's ongoing work on simplifying and streamlining medical device legislation.

Original Documentation

The full title of the Regulation is available in the Official Journal and on EUR-Lex: Commission Implementing Regulation (EU) 2026/977. Summaries of the key points are published in the European Commission's "Medical devices – New regulations" section and in the newsletter of the Directorate-General for Health and Food Safety (DG SANTE).

EUR-Lex — Commission Implementing Regulation (EU) 2026/977: https://eur-lex.europa.eu/eli/reg_impl/2026/977/oj

Sources and Scope of Verification

Sources: European Commission, Implementing Regulation (EU) 2026/977 — summary of key points, https://ec.europa.eu/newsroom/sante/newsletter-archives/75370, published 18 May 2026; European Commission, Medical devices – New regulations, https://health.ec.europa.eu/medical-devices-new-regulations_en; text of the Regulation (EUR-Lex), https://eur-lex.europa.eu/eli/reg_impl/2026/977/oj, published in the Official Journal on 5 May 2026.

Scope of verification and access date: the three official pages above were verified on 3 October 2026. The full text on the EUR-Lex page could not be extracted completely as plain text; the key provisions of the Regulation have therefore been summarized on the basis of the European Commission's official explanatory material.

Applicability note: this article is an interpretation of publicly available EU regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The content of the provisions and their dates of application are subject to the original text published in the Official Journal of the European Union, and the information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

Implementing Regulation (EU) 2026/977 is best understood not as a new set of substantive technical requirements, but as a procedural discipline imposed on notified bodies. For manufacturers, the practical effect is a shift in the balance of the notified body relationship: quotation transparency, maximum processing times and "stop-the-clock" rules create a clearer reference framework for planning and for challenging unreasonable delays, while the annual publication of duration and cost data gives the market a comparable basis for assessing notified body performance.

What manufacturers should expect in practice

• More structured quotations. A quotation should reflect a reliable estimate of the overall scope of services and costs, which makes it easier to budget and to compare notified bodies before signing.
• Maximum timelines at each stage. Application review, contract signing, QMS audits, product verification, decision and certificate issuance, and change assessment each fall under a maximum processing time, improving predictability for launch planning.
• A genuinely usable "stop-the-clock". Time limits are only meaningful if the clock can be paused when information is outstanding; manufacturers should expect disciplined, documented requests for missing documentation and should track their own response times, since delays caused by incomplete submissions remain outside the notified body's control.
• Recertification clarity. Clarified recertification procedures and timetables reduce the risk of certificate lapsing, but they also mean renewal should be planned and resourced well in advance rather than treated as an administrative formality.
• Public performance data. Annual publication of duration and cost information creates a basis for benchmarking notified bodies, though the first reporting year begins only on 1 January 2028.

Points requiring continued attention

The Regulation does not alter classification rules, clinical evaluation requirements, or post-market obligations under the MDR and IVDR, and it does not by itself increase notified body capacity. The practical availability of designated notified body resources, and therefore real-world queue times, will continue to depend on capacity and demand rather than on the Regulation alone.

Business Impact

For global manufacturers, distributors, CROs and regulatory affairs teams, the Regulation affects planning assumptions rather than the technical content of submissions. The key implications are:

• Budget and quotation cycle: quotations become more standardized and comparable, supporting more reliable cost forecasting and more informed notified body selection, including for combination products and IVDs.
• Timeline certainty for market access: maximum processing times and stop-the-clock rules give regulatory affairs teams a documented basis for project scheduling, milestones and escalation, although time spent by the manufacturer in responding remains a variable.
• Recertification planning: clarified procedures and timetables support earlier initiation of renewal activities, reducing the commercial risk of a lapse in certificate validity.
• Notified body selection and monitoring: from 2028, published duration and cost data enable evidence-based comparison of notified bodies and can be used in supplier evaluation and tender documentation.
• Internal process readiness: manufacturers should prepare for more formal, better-documented interactions with notified bodies — complete submission packages, disciplined response times and clear internal ownership of quotation review, contract negotiation and change assessment.
• Timing: with application from 25 February 2027 and reporting obligations from 1 January 2028, the coming months are a preparation window for aligning internal procedures, templates and contractual arrangements with the new framework.

Teams should monitor the Official Journal text and further Commission guidance for the detailed time limits and reporting formats, and should treat the provisions and application dates in the Official Journal as authoritative.

Information Sources

• European Commission — Implementing Regulation (EU) 2026/977: uniform requirements for conformity assessment and notified bodies, 2026-05-05
• EUR-Lex — Commission Implementing Regulation (EU) 2026/977
• European Commission, DG SANTE — Medical Devices: New Implementing Regulation sets out uniform requirements for conformity assessment and notified bodies, 2026-05-18